Researchers investigated the effects of multidisciplinary clinical management of IMDC in patients with NSCLC undergoing treatment with immune checkpoint inhibitors.
Researchers compared the effectiveness of immune checkpoint inhibitor plus SBRT in patients with solid tumors with standard-care ICI monotherapy.
Decreased mobility and depression may be risk factors for irAEs among older adults with advanced cancer who are receiving ICI therapy.
A study evaluated prescribing practices for management of immune-mediated adverse events with immune checkpoint inhibitor therapy at a hospital system.
Very severe immune-related adverse events on immune checkpoint inhibitor therapy occur earlier than less severe ones appear to and may have predictors.
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
Vitamin D may be used to reduce the risk of immune checkpoint inhibitor-related colitis, as well as ulcerative colitis and graft-vs-host disease.
Odds of developing ICI colitis significantly reduced with vitamin D use in patients with melanoma.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
Retrospective study investigated the effect sequence has on overall survival in patients with melanoma brain metastases treated with a combination of SRS, WBRT, immunotherapy, or targeted therapy.
